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ABSTRACT
Background:  Once daily (QD) ritonavir or cobicistat-boosted darunavir (DRV/b), in 
combination with other antiretrovirals (ARVs), is recommended as a first-line option for human 
immunodeficiency virus-infected patients in European and USA guidelines. The objective of this 
study was to analyse the outcomes of DRV/r QD-based antiretroviral therapy (ART) regimens in 
real-life settings.
Methods:  This is an observational, non-interventional, non-comparative, retrospective, 
multicentre cohort study. Data were collected from the databases of eight Belgian AIDS Reference 
Centres. All patients who received at least one dose of DRV/r QD, regardless of background ARV 
regimen, with a minimum follow-up of 6 months were included.
Results: Data from 1701 subjects were collected. Most were male (66.5%) with a mean age of 
42.9  years, 33.1% were treatment-naïve and 66.9% were ART experienced. During a median 
follow-up of 2.45 years (95% CI: 1.50–3.34), the probability to remain on treatment was 87% for 
the first year, 79% for the second year. DRV/r was well tolerated with few discontinuations due 
to adverse events (6.9%) or virological failure (0.8%). Among the 1138 treatment-experienced 
patients, 111 (9.8%) patients received DRV/r QD monotherapy.
Conclusions: This retrospective cohort analysis confirms the long-term effectiveness and good 
tolerability of DRV/r QD in a real-life setting. No unexpected adverse events were reported.
Introduction
Darunavir (DRV) is a human immunodeficiency virus-1 
(HIV-1) protease inhibitor (PI) approved for the treat-
ment of HIV-1 positive subjects [1]. DRV is co-admin-
istered with low-dose ritonavir (DRV/r) or cobicistat 
(DRV/c) as pharmacokinetic boosters. Boosted DRV, 
in combination with other antiretrovirals (ARVs), is 
recommended as a first-line option for HIV-positive 
patients in current guidelines [2,3].
DRV/r 800 mg/100 mg once daily (QD) showed sus-
tained efficacy and was well tolerated in treatment-naïve 
patients in clinical trials (192-week ARTEMIS study [4], 
96-week FLAMINGO study [5] and 96-week ARDENT 
study [6]) as well as in treatment-experienced patients 
with no DRV resistance-associated mutations (ODIN 
study [7]). DRV/r has a high genetic barrier to resist-
ance, as shown in a diverse population of patients treated 
with a DRV 800 mg QD-based regimen and in clinical 
practice in the United Kingdom [8,9].
Several observational studies reflecting routine clini-
cal practice in different countries have demonstrated the 
effectiveness and tolerability profile of DRV/r-containing 
regimens [10–13].
Some observational retrospective studies report the 
use of DRV/r monotherapy as treatment simplification 
strategy, which is however not approved by the European 
Medicines Agency and only recommended in some 
guidelines for a selected group of patients [2,14,15].
DRV/r 800  mg/100  mg QD is available and reim-
bursed in Belgium since 2010, but long-term data in 
real-life clinical settings are limited. The objective of 
this retrospective study was to analyse the use of DRV/r 
800 mg/100 mg QD-based antiretroviral therapy (ART) 
regimens in real-life settings in Belgium. This is also 
relevant as in the meantime two new formulations 
with darunavir have become available in Belgium, a 
fixed-dose-combination with the pharmacological 
booster cobicistat (DRV/c, since 1/12/2015) [16] and a 
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single-tablet regimen (since 1/4/2018) with DRV/c and 
the two NRTIs tenofovir-alafenamide (TAF) and emtric-
itabine (FTC) [17,18], offering new more convenient 
opportunities to integrate DRV into the ART.
Materials and methods
This is an observational, non-interventional, non-com-
parative, retrospective, multicentre cohort study. Data 
were collected from 1 January 2010 to the end of 2014 in 
eight AIDS Reference Centres. The ethics committee of 
each centre approved the study. Patients were included 
if they were ≥18 years of age with a confirmed HIV-1 
infection, treatment-naïve or experienced, had received 
at least one dose of DRV/r 800 mg/100 mg QD with at 
least six months follow-up of their HIV-1 RNA and CD4 
cell count after DRV/r initiation. DRV was administered 
as 2 × 400 mg QD or 1 × 800 mg QD. Patients partici-
pating in ongoing clinical trials were excluded.
Baseline (BL) was defined as the start of DRV/r treat-
ment. Data collected were BL information at DRV/r ini-
tiation, follow-up measurements (after six months and 
after one, two, three and four years of treatment or at the 
last available measure point or until DRV/r was discon-
tinued) and reasons for discontinuation. The primary 
endpoints were time to, rate of and reason for discon-
tinuation of DRV/r treatment, as a simple measure of 
real-world effectiveness. Discontinuation was defined as 
treatment interruption for a period of at least 90 days 
and classified according the D:A:D classification [19]. 
Routine laboratory tests (total cholesterol, HDL choles-
terol, LDL cholesterol, triglycerides, serum creatinine 
and eGFR, with sites using the Cockcroft–Gault or the 
MDRD formula) were documented. An analysis of pre-
vious medical and treatment history was outside the 
scope of this study.
Statistical analyses were performed on all patients 
who initiated DRV 800 mg QD during the study period. 
Demographic and primary analyses were done on the 
overall population using Kaplan–Meier survival analysis 
and log-rank tests to assess outcomes. Analyses on labo-
ratory data were limited to subjects with an observed BL 
(last available value within the six months prior to DRV 
800 mg QD initiation) and at least one post-BL value.
All statistical analyses were performed with the SAS 
program (Statistical Analysis System, Version 9.3).
Results
Baseline characteristics
Data from 1701 HIV-positive patients were collected. 
Most were male (66.5%), of Caucasian (48.6%) or 
of African (29.6%) ethnicity, and the mean age was 
42.9 years. Mode of HIV acquisition was heterosexual in 
42.2% or men who have sex with men (MSM) in 41.6% 
of patients. One-third (33.1%) were treatment-naïve 
(of which 44.2% had a baseline HIV-1 RNA ≥100,000 
copies/mL) and 66.9% were ART-experienced (of 
which 48.5% were virologically suppressed with HIV-1 
RNA  <50 copies/mL). Among naïve patients, 56.5% 
initiated ART with CD4 ≤350 cells/mm3. Most patients 
(59.0%) received a tenofovir disoproxil fumarate/emtric-
itabine (TDF/FTC) backbone, while 11.9% of patients 
did not receive a nucleoside reverse transcriptase inhibi-
tor (NRTI) backbone regimen. DRV/r QD monotherapy 
was used in 6.8%. Demographics and baseline charac-
teristics are shown in Table 1.
Primary endpoints
Probability to remain on treatment
Time to discontinuation of DRV/r, defined as the time 
from first treatment initiation until the end of treat-
ment, is shown in Figure 1 (Kaplan–Meier estimates). 
No significant differences were observed in the subgroup 
analyses between naïve patients with BL HIV-1 RNA 
above or below 100,000 copies/mL (p = 0.3129 log-rank 
test) as well as between experienced patients with a BL 
HIV-1 RNA above or below 50 copies/mL (p = 0.3895 
log-rank test). There were also no differences observed 
when stratified by gender, race, NRTI backbone or base-
line CD4 count.
Overall, 1242 patients (73.0%) remained on DRV/r 
QD treatment as part of their ART during a median fol-
low-up of 2.45 years (Table 2). The probability to remain 
on DRV/r QD treatment was 87.0% for the first year and 
78.9% for the second year.
Reasons for treatment discontinuation
The main reasons for treatment discontinuation were 
treatment simplification (6.7%), adverse events (6.9%, 
4.0% were GI tract related) and patients’ or physicians’ 
decision (3.5%), with minor differences in treatment 
discontinuation rates between naïve and experienced 
patients (Table 3). Discontinuation due to virological 
failure was noted in 13 patients (0.8%) and due to con-
cern of cardiovascular disease and liver toxicity in 3 
patients (0.2%) each.
Secondary endpoints
Probability to maintain virological suppression
Most experienced and naïve patients which responded 
to treatment (HIV-1 RNA  <50 copies/mL, n  =  1504) 
remained virologically suppressed. After 1, 2 and 3 years 
of follow-up 89, 85 and 82% of the patients maintained 
virological suppression. The rate was slightly higher in 
the initially naïve population (94, 90 and 88%) than in 
the treatment experienced (88, 83 and 80%).
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Immunological response
As expected, CD4 cell count at BL was higher in expe-
rienced vs. naïve patients (506 cells/mm3 vs. 312 cells/
mm3). CD4 cell count increased by an average of 
107 cells/mm3 and 330 cells/mm3 in experienced and 
naïve patients, respectively.
Lipids and renal parameters
Laboratory parameters, including lipids (triglycerides, 
cholesterol, HDL-C, LDL-C) and eGFR, remained stable 
throughout the observation period (Table 4).
Analysis of outcome in subjects on DRV/r 
monotherapy
The subgroup of 111/1138 experienced patients without 
previous DRV exposure (9.8%), which initiated DRV/r 
monotherapy, was analysed. The most frequent reasons for 
discontinuation of last ART regimen prior to DRV mono-
therapy were classified as due to ‘Toxicity, predominantly 
from kidneys’ 30% (33/111) and due to the ‘Simplified 
treatment available’ 23.4% (26/111). Compared to the 
overall group of ART experienced patients, patients on 
DRV/r monotherapy were older (mean age 49.5 years vs. 
44.5 years), predominantly of Caucasian ethnicity (65.8% 
vs. 46.0%) and virologically suppressed at baseline (84.7% 
vs. 48.5%). There was no difference in gender and CD4 
nadir (mean 223 cells/mm3 in monotherapy patients vs. 
235 cells/mm3 in other experienced patients).
In the DRV/r QD monotherapy group, 28 of 111 
patients (25.2%) discontinued treatment during a 
median follow-up of 2.55 years and the probability to 
remain on treatment was 81.3% for both the first and 
second years. Whether these subjects discontinued 
DRV/r or intensified their monotherapy regimen with 
additional ARVs is not known. The probability to remain 
on DRV/r in the monotherapy subgroup did not differ 
significantly from the overall cohort on DRV/r QD-
containing combination regimen (73.0%, p = 0.4496 log 
rank test). Mean CD4 nadir in patients (28/111) who 
discontinued monotherapy was 208 and 228 cells/mm3 
for those subjects (83/111) that were still on treatment 
(p  =  0.0781, t-test). A low CD4 nadir (<100 or  <200 
cells/mm3) was not associated with treatment failure. 
The main reasons for treatment discontinuations in 
the group receiving monotherapy were adverse events 
(mainly GI tract disturbances).
Discussion
This retrospective cohort analysis describes the long-
term outcomes with once-daily DRV/r-containing reg-
imens in a diverse patient population in Belgium. The 
DRV/r QD-based regimens had a durable virological 
efficacy and a good tolerability with no major differences 
between treatment-naïve and -experienced patients.
Compared to previous DRV/r trials, some differ-
ences regarding baseline characteristics are notewor-
thy: while previous studies predominantly included 
Caucasian patients (e.g. ~80% in PROTEA [20] and 
~90% in MONET [21]), they only represent half of the 
patients (48.6%) in this cohort. Similar to the Swedish 
InfCare study [22], about one-third of the patients were 
of African ethnicity. More recently published clinical 
Table 1. Baseline characteristics.
athe relatively high-rate of ARt naïve subjects with a Vl <50 copies/ml is 
unusual. in hindsight, some of these subjects might have been on ARt 
before, however did not disclose this to their centre. As centres within 
Belgium have implemented collaborations in exchanging patients’ 
charts, it is assumed that these subjects might have transferred from 
clinics outside of Belgium.
Baseline charac-
teristics
All n = 1701 
(100%)
All Naïve n = 
563 (33%)
All Experi-
enced n = 
1138 (67%)
Mean age, years 
(SD)
42.9 (11.1) 39.8 (10.6) 44.5 (11.0)
gender, n (%) 
 Male 1132 (66.5%) 424 (75.3%) 708 (62.2%)
 Female 569 (33.5%) 139 (24.7%) 430 (37.8%)
ethnicity, n (%) 
 caucasian 826 (48.6%) 302 (53.6%) 524 (46.0%)
 African 503 (29.6%) 112 (19.9%) 391 (34.4%)
 Other 29 (1.7%) 10 (1.8%) 19 (1.7%)
 Unknown 343 (20.2%) 139 (24.7%) 204 (17.9%)
Mode of infec-
tion, n (%)
 Heterosexual 718 (42.2%) 185 (32.9%) 533 (46.8%)
 Homo/bisex-
ual
707 (41.6%) 308 (54.7%) 399 (35.1%)
 injecting drug 
user
35 (2.1%) 8 (1.4%) 27 (2.4%)
 Perinatal 16 (0.9%) 2 (0.4%) 14 (1.2%)
 Other/Un-
known 
225 (13.2%) 60 (10.6%) 165 (14.5%)
HiV-1 RnA, cop-
ies/ml, n (%) 
 <50 563 (33.1%) 11 (2.0%)a 552 (48.5%)
 ≥50 1039 (61.0%) 508 (90.2%) 531 (46.6%)
 Unknown 99 (5.8%) 44 (7.8%) 55 (4.8%)
cD4 cells/mm3, 
mean (SD)
441.8 (287.1) 311.6 (216.2) 506.0 (296.0)
cD4 cells/mm3, 
n (%) 
 <50 122 (7.2%) 71 (12.6%) 51 (4.5%)
 ≥50 and <200 214 (12.6%) 103 (18.3%) 111 (9.8%)
 ≥200 and 
<350
314 (18.5%) 144 (25.6%) 170 (14.9%)
 ≥350 and 
<500
370 (21.8%) 132 (23.4%) 238 (20.9%)
 ≥500 599 (35.2%) 85 (15.1%) 514 (45.2%)
 Unknown 82 (4.8%) 28 (5.0%) 54 (4.7%)
cD4 nadir, mean 
(SD)
249.0 (177.3) 275.8 (184.4) 235.7 (172.2)
current Back-
bone, n (%)
 tDF/Ftc 1003 (59.0%) 409 (72.6%) 594 (52.2%)
 ABc/3tc 259 (15.2%) 84 (14.9%) 175 (15.4%)
 Other 237 (13.9%) 19 (3.4%) 218 (19.2%)
 no nRti 
backbone 






116 (6.8%) 5 (0.9%) 111 (9.8%)
 DRV/r + RAl 47 (2.8%) 29 (5.2%) 18 (1.6%)
 DRV/r + Dtg 12 (0.7%) 9 (1.6%) 3 (0.3%)
 DRV/r + nnRti 8 (0.5%) 1 (0.2%) 7 (0.6%)
 DRV/r + nnRti 
+ RAl
9 (0.5%) 2 (0.4%) 7 (0.6%)
 Other combi-
nations
10 (0.6%) 5 (0.9%) 5 (0.4%)
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Figure 1. time to treatment discontinuation (Kaplan–Meier estimates) for (A) all naïve patients (stratified by Bl HiV-1 RnA <100,000 
copies/ml and ≥100,000 copies/ml) and (B) all experienced patients (stratified by Bl HiV-1 RnA <50 copies/ml and ≥50 copies/ml) 
on a DRV/r QD-containing regimen.
Table 2. Probability to remain on DRV/r QD treatment.
All n = 1701 (100%) All Naïve n = 563 (33%)
All Experienced n = 1138 
(67%)
treatment status, n (%) Remained on DRV/r QD 
treatment
1242 (73.0%) 402 (71.4%) 840 (73.8%)
Discontinued 459 (27.0%) 161 (28.6%) 298 (26.2%)
Median follow-up, years (95% ci) 2.45 (1.50–3.34) 2.42 (1.45–3.29) 2.46 (1.52–3.36)
Probability to remain on DRV/r 
QD treatment (95% ci)
1st year 87.0% (85.2–88.5%) 89.0% (86.0–91.4%) 85.9% (83.8–87.9%)
2nd year 78.9% (76.7–80.9%) 78.2% (74.2–81.7%) 79.2% (76.6–81.6%)
3rd year 69.1% (66.3–71.7%) 64.5% (59.2–69.2%) 71.4% (68.1–74.4%)
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study [18] which evaluated switching to DRV/c/TAF/
FTC in virologically suppressed subjects the median 
baseline CD4 count was high (628 cells/mm3). 94.9% of 
the switched subjects maintained virological suppression 
suppressed after 48 weeks.
The rate of discontinuation of DRV/r QD in this anal-
ysis was low, and rarely due to lack of efficacy. Contrary 
to what would be expected the incidence of virological 
failure was numerically higher in the subjects on first-
line ART (1.2%), than in the experienced subjects (0.5%), 
possibly reflecting the nature of this real-world cohort 
study. No unexpected adverse events were reported and 
the good tolerability that was seen in previous clinical 
studies comparing DRV/r with LPV/r or the integrase 
inhibitors raltegravir and dolutegravir was confirmed 
[4,6,24]. This is in line with the Swedish InfCare study, 
where DRV/r was the most commonly used third agent 
for treatment-experienced patients and showed the low-
est risk for treatment discontinuation [22].
A subgroup of patients received DRV/r monother-
apy. The MONET [21], MONOI [25], PROTEA [20] and 
PIVOT [26] trials have shown that DRV/r monotherapy 
can be considered as a treatment option for patients with 
stable virological suppression on combination therapy 
(HIV-1 RNA  <50 copies/mL for at least six months). 
DRV/r monotherapy has also recently been reported to 
exhibit a good efficacy and safety profile in routine clin-
ical practice [14,15,27]. In this cohort, DRV/r QD mon-
otherapy was well tolerated, adverse events were mainly 
GI related as observed in the MONET and PROTEA 
monotherapy trials [20,28] as well as in another real 
world study from Spain [14].
A low CD4 nadir (<200 cells/μl) has previously been 
shown to be predictive of treatment failure in PROTEA 
[29]. This, however, has neither been observed in our 
cohort nor in a recent observational study [14].
Our study has several limitations, mainly due to its 
observational retrospective design, leading to potential 
selection biases and limited medical history and fol-
low-up details. Information on ART regimens received 
before switch to DRV/r, reasons for switching and details 
of ART-regimens after DRV discontinuation were not 
available, as details on comorbidities, polypharmacy. 
Pre-existing resistance associated mutations (RAMs) 
before commencing DRV-based ART or details on the 
occurrence of RAMs at treatment failure were not sys-
tematically captured at site level and are therefore not 
available in this retrospective real-world cohort analysis.
While the analysis is based on observations ending 
December 2014, the findings inform current treatment 
with boosted DRV, with the two new presentations 
containing cobicistat-boosted darunavir (DRV/c and 
DRV/c/TAF/FTC) which have the potential to increase 
the convenience of DRV-based ART.
trials with DRV/c illustrate how the characteristics of 
patient populations are shifting towards less advanced 
patients and higher rates of treatment success. In the 
AMBER trial [23] which evaluated DRV/c/TAF/FTC 
only 7.0% of the treatment naïve subjects had a baseline 
CD4 cell count ≤200 cells/mm3 vs. 30.9% in this Belgium 
cohort. 91.4% of the treatment naive subjects in AMBER 
had viral suppression after 48 weeks. In the EMERALD 
Table 3. Reasons for treatment discontinuation.
All n = 1701 
(100%)
All Naïve n = 
563 (33%)
All Experi-




459 (27.0%) 161 (28.6%) 298 (26.2%)
Virological 
failure, n (%)
13 (0.8%) 7 (1.2%) 6 (0.5%)
Adverse events, 
n (%)
119 (6.9%) 34 (6.1%) 85 (7.4%)
 Hypersensitiv-
ity reaction
10 (0.6%) 1 (0.2%) 9 (0.8%)
 Abnormal fat 
redistribution
7 (0.4%) 1 (0.2%) 6 (0.5%)
 toxicity – gi 
tract
69 (4.0%) 23 (4.1%) 46 (4.0%)
 toxicity – cnS 5 (0.3%) 1 (0.2%) 4 (0.4%)
 concern of 
cardiovascular 
disease
3 (0.2%) 1 (0.2%) 2 (0.2%)




20 (1.2%) 7 (1.2%) 13 (1.1%)
 Drug interac-
tion








134 (7.9%) 61 (10.8%) 73 (6.4%)
 treatment 
simplification
113 (6.7%) 57 (10.1%) 56 (4.9%)
 non-compli-
ance
21 (1.2%) 4 (0.7%) 17 (1.5%)
Other, n (%) 120 (7.1%) 42 (7. 5%) 78 (6.9%)
 Patients wish/
decision
42 (2.5%) 11 (2.0%) 31 (2.7%)
 Physicians 
decision
17 (1.0%) 6 (1.1%) 11 (1.0%)
 Death 17 (1.0%) 7 (1.2%) 10 (0.9%)
 Other 44 (2.5%) 18 (3.2%) 26 (2.3%)
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Conclusion
This retrospective cohort analysis of patients on DRV/r 
QD in Belgium confirms the long-term efficacy and 
good tolerability of DRV/r QD in a real-life setting. The 
rate of discontinuation of DRV/r QD in daily practice 
was low, and rarely due to lack of efficacy. No unexpected 
adverse events were reported.
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